Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer
Open Access
- 9 June 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 17 (17), 2633-2643
- https://doi.org/10.1093/hmg/ddn163
Abstract
The imprinted insulin-like growth factor 2 (IGF2) gene is expressed predominantly from the paternal allele. Loss of imprinting (LOI) associated with hypomethylation at the promoter proximal sequence (DMR0) of the IGF2 gene was proposed as a predisposing constitutive risk biomarker for colorectal cancer. We used pyrosequencing to assess whether IGF2 DMR0 methylation is either present constitutively prior to cancer or whether it is acquired tissue-specifically after the onset of cancer. DNA samples from tumour tissues and matched non-tumour tissues from 22 breast and 42 colorectal cancer patients as well as peripheral blood samples obtained from colorectal cancer patients [SEARCH (n=case 192, controls 96)], breast cancer patients [ABC (n=case 364, controls 96)] and the European Prospective Investigation of Cancer [EPIC-Norfolk (n=breast 228, colorectal 225, controls 895)] were analysed. The EPIC samples were collected 2–5 years prior to diagnosis of breast or colorectal cancer. IGF2 DMR0 methylation levels in tumours were lower than matched non-tumour tissue. Hypomethylation of DMR0 was detected in breast (33%) and colorectal (80%) tumour tissues with a higher frequency than LOI indicating that methylation levels are a better indicator of cancer than LOI. In the EPIC population, the prevalence of IGF2 DMR0 hypomethylation was 9.5% and this correlated with increased age not cancer risk. Thus, IGF2 DMR0 hypomethylation occurs as an acquired tissue-specific somatic event rather than a constitutive innate epimutation. These results indicate that IGF2 DMR0 hypomethylation has diagnostic potential for colon cancer rather than value as a surrogate biomarker for constitutive LOI.This publication has 59 references indexed in Scilit:
- Distinct Methylation Changes at the IGF2-H19 Locus in Congenital Growth Disorders and CancerPLOS ONE, 2008
- Dnmt3b promotes tumorigenesis in vivo by gene-specific de novo methylation and transcriptional silencingGenes & Development, 2007
- Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancerEuropean Journal of Cancer, 2007
- Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylationNature, 2007
- CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2Proceedings of the National Academy of Sciences of the United States of America, 2006
- Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parametersOncogene, 2004
- Epigenetic Heterogeneity at Imprinted Loci in Normal PopulationsBiochemical and Biophysical Research Communications, 2001
- Deletion of a silencer element in Igf2 results in loss of imprinting independent of H19Nature Genetics, 2000
- Randomised study of screening for colorectal cancer with faecal-occult-blood testThe Lancet, 1996
- Randomised controlled trial of faecal-occult-blood screening for colorectal cancerThe Lancet, 1996